World journal of psychiatry · 2024
Who can benefit more from its twelve-week treatment: A prospective cohort study of blonanserin for patients with schizophrenia.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Xu Bao-Yan, Jin Kun, Wu Hai-Shan, Liu Xue-Jun, Wang Xi-Jin, Sang Hong, Li Ke-Qing, Sun Mei-Juan, Meng Hua-Qing, Deng Huai-Li, Xun Zhi-Yuan, Yang Xiao-Dong, Zhang Lin, Li Guan-Jun, Zhang Rui-Ling, Cai Duan-Fang, Liu Jia-Hong, Zhao Gui-Jun, Liu Long-Fa, Wang Gang, Zhao Chang-Lie, Guo Bin, Jin Sheng-Chun, Huang Ling-Yun, Yang Fu-De, Zheng Jian-Min, Zhan Gui-Lai, Fang Mao-Sheng, Meng Xiang-Jun, Zhang Guang-Ya, Li Hai-Min, Liu Xiang-Lai, Li Ju-Hong, Wu Bin, Li Hai-Yun, Chen Jin-Dong
Аннотация
BACKGROUND: Blonanserin (BNS) is a well-tolerated and effective drug for treating schizophrenia.
AIM: To investigate which types of patients would obtain the most benefit from BNS treatment.
METHODS: A total of 3306 participants were evaluated in a 12-week, prospective, multicenter, open-label post-marketing surveillance study of BNS. Brief psychiatric rating scale (BPRS) scores were calculated to evaluate the effectiveness of BNS, and its safety was assessed with the incidence of adverse drug reactions. Linear regression was used to screen the influencing factors for the reduction of BPRS total score, and logistic regression was used to identify patients with a better response to BNS.
RESULTS: The baseline BPRS total score (48.8 ± 15.03) decreased to 27.7 ± 10.08 at 12 weeks (P < 0.001). Extrapyramidal symptoms (14.6%) were found to be the most frequent adverse drug reactions. The acute phase, baseline BPRS total score, current episode duration, number of previous episodes, dose of concomitant antipsychotics, and number of types of sedative-hypnotic agents were found to be independent factors affecting the reduction of BPRS total score after treatment initiation. Specifically, patients in the acute phase with baseline BPRS total score ≥ 45, current episode duration < 3 months, and ≤ 3 previous episodes derived greater benefit from 12-week treatment with BNS.
CONCLUSION: Patients in the acute phase with more severe symptoms, shorter current episode duration, fewer previous episodes, and a lower psychotropic drug load derived the greatest benefit from treatment with BNS.
AIM: To investigate which types of patients would obtain the most benefit from BNS treatment.
METHODS: A total of 3306 participants were evaluated in a 12-week, prospective, multicenter, open-label post-marketing surveillance study of BNS. Brief psychiatric rating scale (BPRS) scores were calculated to evaluate the effectiveness of BNS, and its safety was assessed with the incidence of adverse drug reactions. Linear regression was used to screen the influencing factors for the reduction of BPRS total score, and logistic regression was used to identify patients with a better response to BNS.
RESULTS: The baseline BPRS total score (48.8 ± 15.03) decreased to 27.7 ± 10.08 at 12 weeks (P < 0.001). Extrapyramidal symptoms (14.6%) were found to be the most frequent adverse drug reactions. The acute phase, baseline BPRS total score, current episode duration, number of previous episodes, dose of concomitant antipsychotics, and number of types of sedative-hypnotic agents were found to be independent factors affecting the reduction of BPRS total score after treatment initiation. Specifically, patients in the acute phase with baseline BPRS total score ≥ 45, current episode duration < 3 months, and ≤ 3 previous episodes derived greater benefit from 12-week treatment with BNS.
CONCLUSION: Patients in the acute phase with more severe symptoms, shorter current episode duration, fewer previous episodes, and a lower psychotropic drug load derived the greatest benefit from treatment with BNS.